WHITEHAWK THERAPEUTICS INC
WHWKNASDAQTrading Snapshot
- Day Range
- $3.25 – $3.51
- 52-Week Range
- $1.97 – $5.50
- Volume (shares)
- 523,161
- Avg Volume (shares)
- —
- Shares Outstanding
- 57.0M
- Next Earnings
- 2026-11-04
Fundamentals Snapshot
- Annual Revenue
- $7M
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- 6.7x
- EPS (TTM)
- $-3.03
- Dividend Yield
- —
- Dilution (1yr)
- +155.5%
WHITEHAWK THERAPEUTICS INC
WHWK
StockOtter · stockotter.spaceAbout WHITEHAWK THERAPEUTICS INC
Whitehawk Therapeutics Inc. is a biopharmaceutical enterprise currently undergoing clinical trials. This company specializes in crafting highly targeted treatment options for cancers that are identified by distinct genetic profiles.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Surrozen (NASDAQ:SRZN) & Whitehawk Therapeutics (NASDAQ:WHWK) Financial Comparison
Surrozen (NASDAQ: SRZN - Get Free Report) and Whitehawk Therapeutics (NASDAQ: WHWK - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on th
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Stock Has Consensus Target Price of $8.33 According to Brokerages
Whitehawk Therapeutics, Inc. (NASDAQ: WHWK - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eight brokerages that are currently covering the company, MarketBeat.com reports. One analyst has r
Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026
MUC16 Expression Remained High and Stable Following Standard-of-Care Therapies, Supporting Its Potential Utility in Both Combination Approaches and Relapsed Settings High MUC16 Expression Was Associated with Poor Real-Wo
Analysts Set Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Price Target at $8.20
Shares of Whitehawk Therapeutics, Inc. (NASDAQ: WHWK - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eight brokerages that are covering the stock, Marketbeat Ratings reports. On
Whitehawk Therapeutics, Inc. (WHWK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Whitehawk Therapeutics, Inc. (WHWK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026PR Newswire